Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of systemic therapies for metastatic pancreatic cancer

(2013) V.C. Tam et al.   Current Oncology

Report triggers quibbles over QALYs, a staple of health metrics

(2013) David Holmes   NATURE MEDICINE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

(2011) J. M. Lohr et al.   ANNALS OF ONCOLOGY

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Average Body Surface Area of Adult Cancer Patients in the UK: A Multicentre Retrospective Study

(2010) Joseph J. Sacco et al.   PLoS One

An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard

(2008) Chris P. Lee et al.   VALUE IN HEALTH

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

(2008) Scott D Grosse   Expert Review of Pharmacoeconomics & Outcomes Research